Sotorasib, a first-in-class KRAS p.G12C inhibitor, has shown significant efficacy in treating KRAS p.G12C-mutant non-small cell lung cancer (NSCLC)7. This evidence concerns the gene KRAS and non-small cell lung carcinoma.